Mabloc and Instituto Butantan Partner to Advance First-in-Class Antibody Therapy for Yellow Fever
Mabloc, a biotechnology company developing monoclonal antibody therapies for multiple disease indications, today announced a strategic partnership with Instituto Butantan, one of the world's leading biomedical research centers, to co-develop and manufacture MBL-YFV-01 – a breakthrough monoclonal antibody therapy for Yellow Fever Virus (YFV) infection, including emergency post-exposure use. https://mma.prnewswire.com/media/2825130/Mabloc_Logo.jpg This partnership comes amid escalating […]